Pfizer's Weight-Loss Drug Faces Efficacy Questions Amidst New Market Entrants.
TL;DR Summary
Pfizer's stock surged after a study showed that its twice-daily pill, danuglipron, led to faster weight loss in patients with type 2 diabetes than Novo Nordisk's once-weekly shot, Ozempic. However, Evercore ISI analyst Umer Raffat warns that Pfizer has not committed to sending danuglipron into Phase 3 testing and is waiting on Phase 2 results of another drug, lotiglipron, which is a once-daily pill and could have a convenience advantage. GLP-1 drugs are gaining steam for their potential to treat obesity, and Pfizer's oral GLP-1 is one of its highest value pipeline programs.
- Pfizer Stock: The One Caveat Investors Missed With Its Ozempic Rival Investor's Business Daily
- Efficacy of Pfizer's weight-loss drug 'inferior' to others on the market, says UBS's Colin Bristow CNBC Television
- Pfizer oral weight loss drug may be as effective as Ozempic injection by Novo Nordisk, study says CNBC
- New Weight-Loss Pills Are Coming. What to Know. Barron's
- Pfizer's weight-loss pill won't be in direct competition with Ozempic, says BMO's Evan Seigerman CNBC Television
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
2 min
vs 3 min read
Condensed
82%
506 → 93 words
Want the full story? Read the original article
Read on Investor's Business Daily